Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Roche returns to Chinese biotech MediLink for another ADC pact - Endpoints News
Roche returns to Chinese biotech MediLink for another ADC pact - Endpoints News
Roche returns to MediLink with $570M near-term payments for ADC - Fierce Biotech
Roche returns to MediLink with $570M near-term payments for ADC - Fierce Biotech
In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech
In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
AI-based Digital Pathology Market Intelligence Report, 2025-2035, Featuring Aiforia Technologies, Ibex Medical Analytics, Indica Labs, PathAI, Roche, Visiopharm and Many Other Key Players - ResearchAndMarkets.com - The AI Journal
AI-based Digital Pathology Market Intelligence Report, 2025-2035, Featuring Aiforia Technologies, Ibex Medical Analytics, Indica Labs, PathAI, Roche, Visiopharm and Man...
Emerson and Roche Collaborate on Digital Modality Library for Pharmaceutical Development - Automation World
Emerson and Roche Collaborate on Digital Modality Library for Pharmaceutical Development - Automation World
Roche Lunsumio VELO bags USFDA approval for subcutaneous use in follicular lymphoma - Medical Dialogues
Roche Lunsumio VELO bags USFDA approval for subcutaneous use in follicular lymphoma - Medical Dialogues
ROG.SW News Today: Trump Drug Plan Boosts Roche Stock on December 22 - Meyka
ROG.SW News Today: Trump Drug Plan Boosts Roche Stock on December 22 - Meyka
Roche and Novartis close to price agreement with Trump - medwatch.com
Roche and Novartis close to price agreement with Trump - medwatch.com
Roche hails giredestrant effect in ER-positive early-stage breast cancer - The Pharma Letter
Roche hails giredestrant effect in ER-positive early-stage breast cancer - The Pharma Letter
Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech
Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech
Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche's Flatiron - Fierce Biotech
Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche's Flatiron - Fierce Biotech
Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing - Yahoo Finance
Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pric...
Global insights on scaling and integrating digital health - Roche
Global insights on scaling and integrating digital health - Roche
Paradigm Health, seeking to use AI to enroll clinical trials, partners with Roche - statnews.com
Paradigm Health, seeking to use AI to enroll clinical trials, partners with Roche - statnews.com
Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron - Endpoints News
Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron - Endpoints News
YuviTal wins Roche-backed breast cancer innovation challenge - JNS.org
YuviTal wins Roche-backed breast cancer innovation challenge - JNS.org
Roche: Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence (RHHBY) - Seeking Alpha
Roche: Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence (RHHBY) - Seeking Alpha